Neuroscience

The British Neuroscience Association (BNA) hosted its 6th International Festival of Neuroscience in April. Atlas Antibodies was there promoting his catalog of primary antibodies for Neuroscience research. Were you also there? Here we briefly summarise the exciting lectures we attended this year.

Understanding the development and progression of lineage cell types within the nervous system is critical for understanding the mechanisms of neurodegeneration and other brain diseases and can help identify potential sites for intervention. Read more and explore our primary antibodies targeting relevant markers in the neural lineage development pathways.

Chiara Musillo, a Ph.D. student from La Sapienza University of Rome, Italy, won the first Atlas Antibodies’ travel grant competition to attend the FENS Forum 2022 in Paris, held in July. Our scientists at Atlas Antibodies selected her research project among many good applications. Here is her story in her own words.

Every career path in neuroscience can be different. Written as a Guest Blog for the British Neuroscience Association BNA, we hear from Dr. Laura Pozzi, our scientific writer, an insightful and inspiring account of her daily life at Atlas Antibodies. Read about the skills and her 3 tips for you to succeed in this job. Enjoy reading!

Primary antibodies are a powerful tool in basic research. In our new research roundup dedicated to neuroscience, we talk about a mechanism responsible for drug resistance in epileptic patients and a newly discovered and evolutionarily conserved feature of oligodendrocytes.

The classification of gliomas is changing profoundly, shifting from a morphology-based guide to a system based on molecular criteria built around their genomic landscape and data from next-generation sequencing. Read more to learn about the key molecular markers that allow the latest classification of gliomas.

Check out this interview with Atlas Antibodies' Principal Scientist, Dr. Eugenia Kuteeva, to hear how our monoclonal antibodies advance discoveries in neurodegenerative diseases. The interview is published on Neuro Central, an online resource powered by Future Science Group.

Our antibodies are used in cutting-edge neuroscience research around the world. Let's take a look at three recent studies showing our antibodies in action.

No effective therapies are currently available for Amyotrophic Lateral Sclerosis- ALS due to the lack of biomarkers for early diagnosis and monitoring disease progression. Dr. Valentina Bonetto applies proteomic assays to find validated biomarkers and innovative therapeutic strategies to treat ALS.

Our highly-validated antibodies and QPrEST protein standards are used in cutting-edge neuroscience research. Read a roundup of some newly published studies to see our neuroscience antibodies and targeted proteomics in action!